¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤¬Ç¾¤ËÎɤ¤Íýͳ¤Ï¡¢·ìή¤òÁý¤ä¤¹¤«¤é¤À¤±¤Ç¤Ï¤Ê¤¤¤è¤¦¤À¡£
Æî¥ß¥·¥·¥Ã¥ÔÂç³Ø¤Î J. V. Smith »á¡¢ Y. Luo »á¤Ë¤è¤ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¥ì¥Ó¥å¡¼¤ò¤´¾Ò²ð¤·¤Þ¤·¤ç¤¦¡£
¡Ö¥®¥ó¥³ ¥Ó¥í¥Ð ¥¨¥¯¥¹¥È¥é¥¯¥È ( ¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹ ) ¤Îʬ»Ò³ØŪ¥á¥«¥Ë¥º¥à¤Ë´Ø¤¹¤ë¸¦µæ¡×
Studies on molecular mechanisms of Ginkgo biloba extract Appl Microbiol Biotechnol (2004) 64: 465¡Ý472 J. V. Smith . Y. Luo
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ë¤Ï£²¤Ä¤ÎÀ®Ê¬¤¬¤¢¤ê¡¢¤½¤ì¤é¤¬¥æ¥Ë¡¼¥¯¤ÊÌôÍýºîÍѤò¤â¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¤È¤³¤í¤«¤é¤³¤Î¥ì¥Ó¥å¡¼¤Ï»Ï¤Þ¤ë¡£
1)¥Æ¥ó¥Ú¥ë
2)¥Õ¥é¥Ü¥Î¥¤¥É
1)¥Æ¥ë¥Ú¥ó¤Ï¼¡¤ËʬÎव¤ì¤ë¡£
a)¥®¥ó¥³¥é¥¤¥É A¡¢B¡¢C¡¢J¡¢M
b)¥Ó¥í¥Ð¥é¥¤¥É
a)¥®¥ó¥³¥é¥¤¥É¤Î¸ú²Ì
¡Ö ¥®¥ó¥³¥é¥¤¥É¤Ï·ì¾®ÈijèÀ²½°ø»Ò (PAF) ¤Î¥¢¥ó¥¿¥´¥Ë¥¹¥È¤Ç¡¢·ì¾®ÈijèÀ²½¤ª¤è¤Ó¶Å½¸¤òÁ˳²¤¹¤ë¡£¤½¤ì¤Ë¤è¤Ã¤Æ·ì±Õ½Û´Ä¤ò²þÁ±¤¹¤ë ¡×¡Ê1¡Ë
¥¢¥ó¥¿¥´¥Ë¥¹¥È¤È¤Ï¤¢¤ëºîÍѤòÁ˳²¤¹¤ëʪ¼Á (Ùɹ³Êª¼Á) ¡£
¤Ä¤Þ¤ê¥®¥ó¥³¥é¥¤¥É¤Ï·ìÀò¤Î·ÁÀ®¤òËɤ°¤³¤È¤¬´üÂԤǤ¤ë¡£
2)¥Õ¥é¥Ü¥Î¥¤¥É¤Î¸ú²Ì
¥Õ¥é¥Ü¥Î¥¤¥É¤Ï¹³»À²½ºîÍѤòȯ´ø¤¹¤ë¡£
¡Ö ¥Õ¥é¥Ü¥Î¥¤¥É¤Ï˧¹á´Ä¤ª¤è¤ÓÆó½Å·ë¹ç¤Ë¤è¤Ã¤Æ¹½À®¤µ¤ì¤Æ¤¤¤ë¡£¤½¤ì¤Ë¤è¤Ã¤Æ¡¢¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤Ë¤è¤êÈ¿±þ¤·¤ä¤¹¤¯¡¢Ä¾ÀÜŪ¥¹¥«¥Ù¥ó¥¸ºîÍѤòͤ¹¤ë ¡×(2)
¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤Ï¥Õ¥ê¡¼¥é¥¸¥«¥ë¡£
¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤Ï¾¤Îʪ¼Á¤ÈÈ¿±þ¤·¤ä¤¹¤¯¡¢Åü¡¢»é¼Á¡¢¥¿¥ó¥Ñ¥¯¡¢£Ä£Î£Á¤ò½ý¤Ä¤±¤ë¡£
¥Ë¥å¡¼¥í¥ó¤ò·ÁÀ®¤¹¤ëʪ¼Á¤Ç¤¢¤ëÉÔË°Ï»éËûÀ¤ËÂФ·¤Æ¤â¡¢¤³¤Î¥é¥¸¥«¥ë¤¬»À²½¥À¥á¡¼¥¸¤òÍ¿¤¨¤ë¡£
¥Õ¥é¥Ü¥Î¥¤¥É¤Ï¤Ä¤Þ¤ê¥Ë¥å¡¼¥í¥ó¤ò»À²½¤«¤é¼é¤ë¤³¤È¤¬´üÂԤǤ¤ë¡£
¤µ¤é¤Ë
¡Ö SOD ( superoxide dismutase ) ¤Î¤è¤¦¤Ê¹³»À²½¥¿¥ó¥Ñ¥¯¼Á¤Îȯ¸½¡¢¥°¥ë¥¿¥Á¥ª¥ó¤Î¤è¤¦¤Ê¹³»À²½Âå¼Õʪ¼Á¤òÁý²Ã¤µ¤»¤ë ¡×(3)¡¨(4)
SOD¤È¤ÏÁ°½Ð¤Î¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤ò̵³²²½¤¹¤ë¹ÚÁǤΤ³¤È¡£
¤È¤³¤í¤¬SOD¤Ï²ÃÎð¤Ëȼ¤¤¸º¾¯¤·¤Æ¤·¤Þ¤¦¡£
¤·¤«¤·¥Õ¥é¥Ü¥Î¥¤¥É¤ÏSOD¤òÁý²Ã¤µ¤»¤ë¡£
¡Ö ¥Õ¥é¥Ü¥Î¥¤¥É¾å¤Î¿å»À´ð¤Ï prooxidant transitional metal ions (Î㤨¤ÐFe2+) ¤È·ë¹ç¤·¤Æ¥¥ì¡¼¥È´Ä¤òºî¤ë ¡×(3)
¡Ö ¤½¤ì¤Ë¤è¤ê¿·¤¿¤Ê¥Ò¥É¥í¥¥·¥é¥¸¥«¥ë¤ÎÀ¸À®¤òÁ˳²¤¹¤ë ¡×(2)¡¨(5)
Å´¤Ï»¬¤Ó¤ä¤¹¤¤¡£
¤½¤ì¤ÏÀ¸ÂÎÆâ¤ÎÅ´¤Ç¤âƱ¤¸¤Ç¤¹¡£
¾åµ¤Ï¡¢¥Õ¥é¥Ü¥Î¥¤¥É¤¬Å´¤ÈÈ¿±þ¤·¤Æ»À²½¤òËɤ°¤È¤¤¤¦Êó¹ð¡£
¤½¤ì¤Ç¤Ï¤½¤ì¤éÀ®Ê¬¤ò´Þ¤à¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¼çÍפʸú²Ì¤Ë¤Ä¤¤¤Æ¡£
£± ¥Õ¥ê¡¼¥é¥¸¥«¥ë¡¢»À²½¥¹¥È¥ì¥¹¤Ë¤Ä¤¤¤Æ
¡Ö ¥Õ¥ê¡¼¥é¥¸¥«¥ë¥¹¥«¥Ù¥ó¥¸¥ã¡¼³èÀ²½ºîÍѤò¤â¤Ã¤Æ¤¤¤ë ¡×
¡Ö ROS ( reactive oxygen species ) ¤ÎÁÈ¿¥ÆâÇ»ÅÙ¤ò¸º¾¯¤µ¤»¤ë ¡×(6)¡¨(7)¡¨(8)
ROS ( ³èÀ»ÀÁǼï ) ¤È¤Ï¥Õ¥ê¡¼¥é¥¸¥«¥ë¡¢³èÀ»ÀÁǤÎÁí¾Î¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¤½¤ì¤ò¸º¤é¤¹¤È¤¤¤¦¡¢¤³¤ì¤Ï¹³»À²½ºîÍѤˤĤ¤¤Æ¤ÎÊó¹ð¡£
¡Ö Ëì»é¼Á²á»À²½È¿±þ¤òÍÞÀ©¤¹¤ë ¡×(6)
Ëì»é¼Á²á»À²½È¿±þ¤È¤Ï¡¢»é¼Á¤Î»À²½¤¬Ï¢º¿¤¹¤ë¤È¤¤¤¦¸½¾Ý¤Î¤³¤È¡£
¤¢¤ë¤¤Ã¤«¤±¤Ç¿åÁǤò°ú¤È´¤«¤ì¤¿»é¼Á¤Ï¡¢¥Õ¥ê¡¼¥é¥¸¥«¥ë¤È²½¤¹¡£
¤½¤ì¤¬¤³¤ÎÏ¢º¿¤Î»Ï¤Þ¤ê¡£
¥é¥¸¥«¥ë²½¤·¤¿»é¼Á¤Ï¾¤Îʪ¼Á¤«¤éÅŻҤòÃ¥¤¤¥é¥¸¥«¥ë¤òÁý¤ä¤·¤Æ¤æ¤¯¡£
Áý¤¨¤¿¥é¥¸¥«¥ë¤Ï·òÁ´¤Ê»é¼Á¤Î¿åÁǤò¤Ä¤®¤Ä¤®°ú¤¤Ì¤¯¡£
¤È¤¤¤¦¤è¤¦¤Ë¡¢Ëì»é¼Á²á»À²½È¿±þ¤È¤Ï¡¢¤¤¤ï¤Ð»é¼Á¥¾¥ó¥Ó²½¸½¾Ý¡£
¤½¤·¤Æ¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¤½¤ÎÏ¢º¿È¿±þ¤òÍÞÀ©¤¹¤ëƯ¤¤òͤ¹¤ë¡£
¤Á¤Ê¤ß¤Ë¡¢
¥Ó¥¿¥ß¥óE¤â»é¼Á¥é¥¸¥«¥ë¤ò¸µ¤ËÌ᤹ʪ¼Á¡£
¤¿¤À¤·¡¢¥Ó¥¿¥ß¥ó£Å¤Î¥µ¥×¥ê¥á¥ó¥ÈÀݼè¤Ï¿Î̤ˤʤê¤ä¤¹¤¯ÃæÀ»éËäò°ú¤¾å¤²¤«¤Í¤Ê¤¤¤Î¤ÇÃí°Õ¤¬É¬Íס£
»é¼Á¤Î»À²½¤òËɤ°¤¿¤á¤Î¥µ¥×¥ê¥á¥ó¥È¤òÁª¤Ö¤Ê¤é¡¢¥Õ¥é¥Ü¥Î¥¤¥É¤¬Îɤ¤¤Ç¤·¤ç¤¦¡£
2 ¹³¥¹¥È¥ì¥¹ºîÍÑ
¡Ö Éû¿ÕÈé¼Á¤ÎPBR ( peripheral-type benzodiazepine receptor ) ¤Îȯ¸½¤ò¸º¤é¤¹ ¡×(6)
PBR¤È¤Ï¡¢Ëö¾¿·¿¥Ù¥ó¥¾¥¸¥¢¥¼¥Ô¥ó¼õÍÆÂΤΤ³¤È¤Ç¥³¥ë¥Á¥¾¡¼¥ë¤Î¹çÀ®¤Ë¤«¤«¤ï¤ë¼õÍÆÂΤΤ³¤È¡£
Éû¿ÕÈé¼Á¤Ë¿¤¯Â¸ºß¤·¤Æ¤¤¤ë¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¥³¥ë¥Á¥¾¡¼¥ë¤ÎÀ¸»ºÎ̤ò¸º¤é¤¹¤è¤¦¤Ç¤¢¤ë¡£
¥³¥ë¥Á¥¾¡¼¥ë¤ÏÀ¸Â¸¤ËÉԲķç¤Ê¥Û¥ë¥â¥ó¤Ç¤Ï¤¢¤ë¤â¤Î¤Î¡¢À¸ÂΤËÍÍ¡¹¤Ê¾ã³²¤ò°ú¤µ¯¤³¤¹¥Û¥ë¥â¥ó¤Ç¤â¤¢¤ë¡£
¤¿¤È¤¨¤Ð¥³¥ë¥Á¥¾¡¼¥ë¤ÎÂçÎÌȯÀ¸¡¢¤¹¤Ê¤ï¤Á¥¹¥È¥ì¥¹¤Ï¡¢³¤ÇϤò°Ñ½Ì¤µ¤»¤«¤Í¤Þ¤»¤ó¡£³¤ÇϤΥ˥塼¥í¥ó¤¬»àÌǤ·¤Æ¤¤¤Þ¤¹¡£
³¤ÇϤˤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤ¬Â¿¤¯¤¢¤ê¤Þ¤¹¡£
¡ÊÊ¢Éô¤â¿¤¯¤Æ¡¢¤À¤«¤é¥¹¥È¥ì¥¹¤Ï¤Ò¤È¤òÂÀ¤é¤»¤ë¡£¤¬¡¢¤½¤ì¤Ï¤Þ¤¿Ê̤ʵ¡²ñ¤Ë¡Ë
³¤ÇϤÏÀ¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤È¡Ö¸Æ¤Ó¤«¤±¤ë¡×´ï´±¤Ç¤¢¤ë¤¿¤á¡¢¥³¥ë¥Á¥¾¡¼¥ë¤ÎÌðÌ̤ËΩ¤Ä»ÅÁȤߤǤ¹¡£
¤·¤«¤·²á¾ê¤Ê¥³¥ë¥Á¥¾¡¼¥ë¤Ï¡ÊËýÀŪ¤Ê¥¹¥È¥ì¥¹¤Ï¡Ë³¤ÇϤΥ˥塼¥í¥ó¤ò¡Ö¶½Ê³ÆÇÀ»à¡×¤Ø¤ÈÄɤ¤¹þ¤ß¤«¤Í¤Þ¤»¤ó¡£
¡Ö¶½Ê³ÆÇÀ»à¡×¤È¤¤¤¦¸½¾Ý¤Ï¥Ë¥å¡¼¥í¥ó¤¬»àÌǤ¹¤ë»ÅÁȤߤΤҤȤĤǤ¹¡£
²á¾ê¤Ë»É·ã¤µ¤ì¤¿¥Ë¥å¡¼¥í¥óÆâ¤Ë¥«¥ë¥·¥¦¥à¥¤¥ª¥ó¤¬ÂçÎ̤ËήÆþ¤·¡¢¥Ë¥å¡¼¥í¥ó¤¬¶½Ê³¾õÂ֤Ȥʤꡢ²á³èÆ°¤òµ¯¤³¤·¡¢Èè¤ì²Ì¤Æ¡¢»àÌǤ¹¤ë¡¢¤È¤¤¤¦¸½¾Ý¡£
³¤ÇϤε¡Ç½¤Ë¤Ä¤¤¤Ï¤´¾µÃΤȻפ¤¤Þ¤¹¤¬¡¢Ç°¤Î¤¿¤á¡£
³¤ÇϤϵ²±¤òÄêÃ夵¤»¤¿¤êµ²±¤ò¸Æ¤Óµ¯¤·¤¿¤ê¤¹¤ëµ²±¤ÎÅý¹ç´ï´±¤Ç¤¢¤ê
¤Þ¤¿³¤ÇϤÏÀ¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤Èž¤¸¤ë¥¹¥¤¥Ã¥Á¤Ç¤â¤¢¤ë¡£
²Ã¤¨¤Æ³¤ÇϤÏÂç¿Í¤Ç¤¢¤Ã¤Æ¤â¥Ë¥å¡¼¥í¥ó¤¬¿·À¸¤·¡¢°é¤Ä¾ì½ê¡£
¡Ö Ǿ¤Î¥â¥Î¥¢¥ß¥ó»À²½¹ÚÁÇ ( MAO ) ³èÀ¤òÄã²¼¤µ¤»¤ë ¡×(9)
MAO ( ¥â¥Î¥¢¥ß¥ó¥ª¥¥·¥À¡¼¥¼ ) Á˳²Ìô¤ÏǾ¤Î¥É¡¼¥Ñ¥ß¥óÇ»ÅÙ¤ò¾å¤²¤ë¡£
MAOÁ˳²Ìô¤Ï¡¢¥¢¥á¥ê¥«¤Ç¤Ï¹³¤¦¤ÄºÞ¤È¤·¤Æ¤â»È¤ï¤ì¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£
¤³¤ì¤¹¤Ê¤ï¤Á¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¹³¤¦¤ÄºîÍѤò¼¨¤¹Êó¹ð¤Ç¤¹¡£
3 ¥Ë¥å¡¼¥í¥ó¤Î¥¢¥Ý¥È¡¼¥·¥¹¤Ø¤ÎºîÍÑ
¡Ö ¥Ë¥å¡¼¥í¥ó¤Î¥¢¥Ý¥È¡¼¥·¥¹¤Î¸º¾¯ ¡×(10)¡¨(11)¡¨(12¡Ë
¥¢¥Ý¥È¡¼¥·¥¹¤È¤Ï¥×¥í¥°¥é¥à¤µ¤ì¤¿ºÙ˦¤Î»àÌÇ¡¢ºÙ˦¤Î¼«»¦¤È¸À¤ï¤ì¤ë¸½¾Ý¤Ç¡¢¥Ë¥å¡¼¥í¥ó»àÌǸ¶°ø¤Î¤Ò¤È¤Ä¡£
4 ǧÃε¡Ç½¡¢µ²±¤Ø¤Î¸ú²Ì
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤ÎÉÕÃå¤ò²þÁ±¤¹¤ë¤È¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¡Ö ¿À·Ð²êºÙ˦¼ðºÙ˦¤Ë¤ª¤±¤ë¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Î¶Å½¸ÍÞÀ© ¡×(11)
¡Ö °Õ»×·èÄêǽÎϤä¹âÎðưʪ¤Ë¤ª¤±¤ë¿·¤·¤¤¥¹¥¥ë¤Î½¬ÆÀ¡¢¥¹¥È¥ì¥¹¤Ø¤Î±þÅú¤äµ¤Ê¬¤ÎÊѲ½¤È¤¤¤Ã¤¿°ø»Ò¤ËÂФ·¤ÆÍ±× ¡×(9)¡§(13)
£Ä£Î£Á¤¬Â»½ý¤ò¼õ¤±¡¢°Û¾ï¤Ê¥«¥¿¥Á¤Î¥¿¥ó¥Ñ¥¯¼Á¤òºî¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£
¤¿¤È¤¨¤ÐǾÆâ¤Ë¤ª¤¤¤Æ¤Ï¡¢¥¿¥ó¥Ñ¥¯¼Á¤ÎÀ½Â¤¤Î²áÄø¤Ç¡¢ËÜÍè¡¢Æ⦤ËÀޤꤿ¤¿¤Þ¤ì¤ë¤Ù¤ÌýÀÉôʬ¤¬³°¤Ë¤à¤½Ð¤·¤È¤Ê¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£
¤½¤ì¤é°Û¾ï¤Ê¥¿¥ó¥Ñ¥¯¼ÁƱ»Ö¤ÏÌþÃ夷¡¢²ô¤È²½¤·¤Æ¤æ¤¯¡£
¤³¤Î²ô¤Ï¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤È¸Æ¤Ð¤ì¤Þ¤¹¡£
¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Ï¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤θ¶°ø¤Î¤Ò¤È¤Ä¤È¤â¸«¤é¤ì¤Æ¤¤¤Þ¤¹¡£
¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤¬ÉÕÃ夷¤¿¥Ë¥å¡¼¥í¥ó¤Ï¤ä¤¬¤Æ¿ê¼å¤·¡¢»àÌǤ¹¤ë¤³¤È¤¬Ê¬¤«¤Ã¤Æ¤¤¤Þ¤¹¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¤½¤Î¿ê¼åÃʳ¬¤Ë¤¢¤ë¥Ë¥å¡¼¥í¥ó¤ò²óÉü¤µ¤»¤ë¤È¤ÎÊó¹ð¤â¤¢¤ê¤Þ¤¹¡£
¾åµ¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤¬¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Î·ÁÀ®¤òÍÞÀ©¤¹¤ë¤È¤¤¤¦Êó¹ð¤Ç¤¹¡£
¤Á¤Ê¤ß¤Ë¤³¤Î¥ì¥Ó¥å¡¼¤Ë¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Îµ²±ÎϲþÁ±ºîÍѤòÊó¹ð¤¹¤ëÏÀʸ¤Î°úÍѤϤ¢¤ê¤Þ¤»¤ó¤¬¡¢¤½¤Î²ÄǽÀ¤ò¼¨¤¹ÏÀʸ¤ò¸«¤Ä¤±¤ë¤³¤È¤Ï¤Ç¤¤Þ¤¹¡£
ʬ»Ò¥ì¥Ù¥ë¤Ç¤Ï¡¢¤¿¤È¤¨¤Ð NDMA¼õÍÆÂΡÊĹ´üµ²±¤Ë´Ø·¸¤¹¤ë¼õÍÆÂΡˤΥΥ寥¢¥¦¥È¥Þ¥¦¥¹¤Ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤òÍ¿¤¨¡¢µ²±ÎϤ¬Ìá¤Ã¤¿Åù¡¢Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
5 ·ì±Õ¡¢·ìή¡¢·ì´É¤Ø¤ÎºîÍÑ
¡Ö ·ì¾®ÈijèÀ²½°ø»Ò PAF ÍÞÀ©¸ú²Ì¤Ë¤è¤ëǾµõ·ì¤Î²þÁ± ¡×(10)
¡Ö ÆâÈéͳÍè·ì´ÉÃд˰ø»Ò EDRF (Stimulation of endothelium-derivedrelaxing factor) ¤Î»É·ã¤Ë¤è¤ëÆ°Ì®¡¢ÀÅÌ®¤ª¤è¤ÓÌӺٴɤν۴IJþÁ± ¡×(14)
·ì´É¤Î¤â¤Ã¤È¤âÆ⦤˸ºß¤¹¤ëÆâÈé¤ÏÍÍ¡¹¤Êʪ¼Á¤òʬÈ礷¤Þ¤¹¡£
EDRF (NO °ì»À²½ÃâÁÇ) ¤â¤½¤Î¤¦¤Á¤Î¤Ò¤È¤Ä¡£
°ì»À²½ÃâÁǤϷì´É¤òÃдˤµ¤»¤ë¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤¬·ìή¤òÎɤ¯¤¹¤ë¤È¤¤¤¦¤Î¤Ï¤³¤Î¤¿¤á¤È¹Í¤¨¤é¤ì¤ë¡£
5 ¿À·ÐÅÁãʪ¼Á¤Ø¤ÎºîÍÑ
¡Ö ǾÆâ¤Î¦Á1-¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΡ¢5-HT1A ( ¥»¥í¥È¥Ë¥ó ) ¼õÍÆÂΤª¤è¤Ó¥à¥¹¥«¥ê¥ó¼õÍÆÂΤÎǯÎð¤Ë¤è¤ë¸º¾¯Í½ËÉ ¡×(6)
¡Ö ³¤ÇϤιâ¿ÆÏÂÀ¥³¥ê¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤Î¼è¤ê¹þ¤ß¤ÎÁý²Ã ¡×(6)
¥·¥Ê¥×¥¹Á°ºÙ˦¤«¤éÊü½Ð¤µ¤ì¤¿¥¢¥»¥Á¥ë¥³¥ê¥ó¤Ï¡¢¥·¥Ê¥×¥¹¸åºÙ˦¤Î¼õÍÆÂΤò³èÀ²½¤·¤¿¤¢¤È¤Ç¡¢µÞ®¤Ëʬ²ò¤µ¤ì¤Þ¤¹¡£ ¥³¥ê¥ó¥¨¥¹¥Æ¥é¡¼¥¼¤Ë¤è¤Ã¤Æ¥³¥ê¥ó¤È¿Ý»À¤Ë¡£
¥·¥Ê¥×¥¹¤Ï¿®¹æÅÁã¤ò¤¹¤ë¤¿¤á¤Ë¥¢¥»¥Á¥ë¥³¥ê¥ó¤òºÆÅÙ¡¢ÊÝͤ·¤Ê¤±¤ì¤Ð¤Ê¤ê¤Þ¤»¤ó¡£
¤·¤«¤·¥Ë¥å¡¼¥í¥ó¤Ï¥¢¥»¥Á¥ë¥³¥ê¥ó¤Î¸¶ÎÁ¤Ç¤¢¤ë¥³¥ê¥ó¤òºî¤ì¤Þ¤»¤ó¤Î¤Ç¡¢Ê¬²ò¤µ¤ì¤Æ¼þ°Ï¤òɺ¤¦¥³¥ê¥ó¤ò¡¢ºÆÅÙ¡¢¥·¥Ê¥×¥¹Æâ¤Ë¼è¤ê¤³¤àɬÍפ¬¤¢¤ê¤Þ¤¹¡£
³¤ÇϤιâ¿ÆÏÂÀ¥³¥ê¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤È¤Ï¡¢¤½¤ì¤é¥³¥ê¥ó¤Î¼è¤ê¹þ¤ß¸ý¤Î¤³¤È¤Ç¤¹¡£
¤Ä¤Þ¤ê¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¥¢¥»¥Á¥ë¥³¥ê¥ó¤òÁý¤ä¤¹¤è¤¦¤Ç¤¹¡£¡Ê¥³¥ê¥ó¤Î¥ê¥µ¥¤¥¯¥ë¸úΨ¤ò¸þ¾å¤µ¤»¤ë¡Ë¡Ê¤Á¤Ê¤ß¤Ë¹âÎï¿Í»²¥¨¥¥¹¤Ë¤â¤³¤ÎƯ¤¤¬¤¢¤ê¤Þ¤¹¡Ë
¥¢¥»¥Á¥ë¥³¥ê¥ó¤Ï¡¢µ²±¤Î·ÁÀ®¡¢³Ø½¬¡¢¹ÔÆ°¡¢¿ç̲¤Ë´Ø·¸¤¹¤ë¿À·ÐÅÁãʪ¼Á¤Ç¤¢¤ë¤³¤È¤Ï¤´¾µÃΤ«¤È»×¤¤¤Þ¤¹¡£
7 ¹³¥¹¥È¥ì¥¹ºîÍÑ¡¢°äÅÁ»Òȯ¸½¤Ø¤ÎºîÍѤʤÉ
¡Ö ³¤ÇϤΥ°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤΥÀ¥¦¥ó¥ì¥®¥å¥ì¡¼¥·¥ç¥ó¤ÎÁ˳² ¡×(6)
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¡¢¥¹¥È¥ì¥¹¤Ø¤ÎÄñ¹³ÎϤò¹â¤á¤ë¤È¤¤¤¦Êó¹ð¡£
³¤ÇϤΥ°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤθº¾¯¤ò¤¯¤¤¤È¤á¤ë¤È¤¤¤¦¤³¤ÎºîÍѤϡ¢¤¢¤ë¼ï¤Î¹³¤¦¤ÄÌôƱÍͤÎƯ¤¡£
¥°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤȤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤǤ¹¡£
¤½¤Î¼õÍÆÂΤγèÀ²½¤È¤Ï¡¢À¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤ÈÀÚ¤êÂؤ¨¤ë¤¿¤á¤Ë½ÅÍס£
³¤ÇϤˤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤ¬Â¿¤¯¤¢¤ê¡¢¤½¤ì¤æ¤¨²á¾ê¤Ê¥³¥ë¥Á¥¾¡¼¥ë¤Ï³¤ÇϤòÇ˲õ¤¹¤ë¤È¤¤¤¦¤Î¤¬Àè¤Û¤É¤Î¤ªÏä·¡£
¡Ö ¤¢¤ëÆÃÄê¤Î°äÅÁ»Ò¤Îž¼Ì¤òÄ´À᤹¤ë¡£¤½¤Î·ë²Ì¡¢ºÙ˦¤Î¹³»À²½¾õÂÖ¤òÁý²Ã¤µ¤»¡¢»À²½¥¹¥È¥ì¥¹ÂÑÀ¤ò¶¯²½¡¢ÅÁ㥢¥»¥Á¥ë¥³¥ê¥ó¤ÎÎ̤âÁý¤¨¤ë¡×(15)
¡Ö DNA¹çÀ®¤ä½¤Àµ¡¢ºÙ˦¼þ´ü¤Ë¤ª¤±¤ëµ¡Ç½¤Ë´Ø¤ï¤ë¥¿¥ó¥Ñ¥¯¼Á¤ÎÊѲ½¤Ë±Æ¶Á¤ò¤¢¤¿¤¨¡¢DNA»½ý¤òÍÞÀ©¤¹¤ë¡×(15)
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï°äÅÁ»Òȯ¸½¤ËºîÍѤ·¡¢¹³»À²½ÎϤζ¯¤¤¥Ë¥å¡¼¥í¥ó¤Ë¶¯²½¤¹¤ëƯ¤¤òͤ¹¤ë¡£
8 ¤½¤Î¾
¡Ö ¥ß¥È¥³¥ó¥É¥ê¥¢¤Î¸ÆµÛÄ´ÀáÈæΨ¤ÎÁý²Ã¤Ë¤è¤ëATP¥ì¥Ù¥ë¤òÁý²Ã ¡×(1)
¤³¤ì¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤ÏÀ¸ÂÎÆâ¤Î¥¨¥Í¥ë¥®¡¼¤òÁý¤ä¤¹¤È¤¤¤¦Êó¹ð¡£
¤Û¤«¤Ë¤â¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¹â»³É¤Ë͸ú¤Ç¤¢¤ë¤È¤¤¤¦Êó¹ð¤â¤¢¤ë¡£
¤³¤ì¤¬°ÕÌ£¤¹¤ë¤Î¤Ï»ÀÁǤμè¤ê¹þ¤ß¸úΨ¤ò¾å¤²¤ë¤È¤¤¤¦¤³¤È¤Ç¤¹¡£
Æü¾ïÀ¸³è¤Î¤Ê¤«¤Ç¤â»ÀÁǤμè¤ê¹þ¤ß¤Î¸º¤ë»öÂ֤Ϥ¿¤Ó¤¿¤ÓÀ¸¤¸¤Þ¤¹¡£
½¸Ã椹¤ë¤È¤¡¢¤ï¤¿¤·¤¿¤Á¤Ï¸ÆµÛ¤ò¤Ä¤¤Ëº¤ì¤¬¤Á¡£
½¸Ã椷¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤È¤¤Ë¤Ï¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤òÀݤê¤Þ¤·¤ç¤¦¡£
¡Ö ¹³±ê¾ÉºîÍѤª¤è¤ÓǾ¾ã³²¤ËÂФ¹¤ëÊݸîºîÍÑ ¡×(16)
¡Ö ¿À·Ð¤Î²ÄµÕÀ¤Ø¤Î±Æ¶Á ¡×(6)¡¨(3)
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¼å¤Ã¤¿¥Ë¥å¡¼¥í¥ó¤ò²óÉü¤µ¤»¤ë¤è¤¦¤Ç¤¢¤ë¡£
¤·¤«¤·¤³¤³¤Ç¤ÎÌäÂê¤Ï¡¢¥Õ¥Ä¥¦¤Î¤Ò¤È¡¢¤Ç¤Ï¤Ê¤¯¡¢Æ¬Ç¾Àï»Î¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¥Ý¥Æ¥ó¥·¥ã¥ë¤ò¤É¤¦°ú¤½Ð¤¹¤«¡¢¤È¤¤¤¦¤³¤È¤Ç¤·¤ç¤¦¡£
¤ª´«¤á¤¹¤ë¤Î¤Ï¡¢¹âÎï¿Í»²¥¨¥¥¹¤ä¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÈÁȤ߹ç¤ï¤»¤ë¤³¤È¤Ç¤¹¡£
¹âÎï¿Í»²¥¨¥¥¹¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹Æ±ÍÍ¡¢¡Ö¶½Ê³ÆÇÀ»à¡×¤òÍÞ¤¨¤ëƯ¤¡¢¥¢¥»¥Á¥ë¥³¥ê¥ó¤òÁý¤ä¤¹Æ¯¤¤â´üÂԤǤ¤Þ¤¹¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤ÈÁȤ߹ç¤ï¤»¤¿¼Â¸³¤Ç¤Ï¡¢ADHD¤ò²þÁ±¤¹¤ëÊó¹ð¤â¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
½¸ÃæÎϤò¹â¤á¤ë¤³¤È¤¬´üÂԤǤ¤ë¤Î¤Ç¤¹¡£
¤µ¤é¤Ë¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤È¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÎÁȤ߹ç¤ï¤»¤Ë¤Ï¡¢½¸ÃæÎÏ¡¢µ²±ÎϤò²þÁ±¤µ¤»¤ë¤³¤È¤âÊó¹ð¤â¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¤½¤ì¤é¥µ¥×¥ê¥á¥ó¥È¤ò¸ÄÊ̤˹ØÆþ¤·¡¢¼«Ê¬¤Ë¹ç¤¦¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¡¦¥¹¥¿¥Ã¥¯¤ò¸«¤Ä¤±¤Æ¤ß¤Æ¤Ï¤¤¤«¤¬¤Ç¤·¤ç¤¦¤«¡£
¤¢¤ë¤¤¤Ï
¥¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¤ä¡¢¥¯¡¼¥ë¥¹¥¦¥£¥Ã¥Á COOL SWITCH¤Ë¤Ï¡¢¤½¤ì¤éÊó¹ð¤È¤Û¤ÜƱÎ̤Υ¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¡¢¹âÎï¿Í»²¥¨¥¥¹ (COOL SWITCH¤Ï¥¢¥á¥ê¥«¿Í»²)¡¢¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¡¢¥Ð¥³¥Ñ¥â¥Ë¥¨¥é¥¨¥¥¹¤¬Ç۹礵¤ì¤Æ¤¤¤Þ¤¹¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤òñÆȤÇÀݤë¾ì¹ç¤È¡¢¥¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¡¢COOL SWITCH ¤È¤ò°û¤ßÈæ¤Ù¤Æ¤ß¤ë¤Æ¤âÌÌÇò¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£
¥¹¥¦¥£¥Ã¥Á¤Ï¡¢¥¢¥Þ¥¾¥ó¤ä³ÚÅ·¤Ç¤âÆþ¼ê¤Ç¤¤Þ¤¹¡£
¢§¥¢¥Þ¥¾¥ó COOL SWITCH
https://www.amazon.co.jp/dp/B07P9XSK2G/
¢§¥¢¥Þ¥¾¥ó SWITCH
https://www.amazon.co.jp/dp/B0095GON76
¢§¥¢¥Þ¥¾¥ó HYPER SWITCH
https://www.amazon.co.jp/dp/B012QKWVMQ
References
(1)¡¡Defeudis FV (2002a) Bilobalide and Neuroprotection. Pharmacol
Res 46:565¡Ý568
(2)¡¡Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M (2002)Ginkgo biloba extract: from molecular mechanisms to the
treatment of Alzheimer's disease. Cell Mol Biol 48:613¡Ý623
(3)¡¡Gohil K, Packer L (2002) Global gene expression analysis identifiescell and tissue specific actions of Ginkgo biloba extract, EGb761. Cell Mol Biol 48:625¡Ý631
(4)¡¡Oken B, Storzbach D, Kaye J (1998) The efficacy of Ginkgo bilobaon cognitive function in Alzheimer disease. Arch Neurol55:1409¡Ý1415
(5)¡¡Ni Y, Zhao B, Hou J, Xin W (1996) Preventive effect of Ginkgobiloba extract on apoptosis in rat cerebellar neuronal cellsinduced by hydroxyl radicals. Neurosci Lett 214:115¡Ý118
(6)¡¡DeFeudis F, Drieu K (2000) Ginkgo biloba extract (EGb 761) andCNS functions: basic studies and clinical applications. CurrDrug Targets 1:25¡Ý58
(7)¡¡Lien E, Ren S, Bui H, Wang R (1999) Quantitative structure-activityrelationship analysis of phenolic antioxidants. Free Radic BiolMed 26:285¡Ý294
(8)¡¡Smith J, Luo Y (2003) Elevation of oxidative free radicals inAlzheimer's disease models can be attenuated by Ginkgo bilobaextract EGb 761. J Alzheimer's Dis 5:287¡Ý300
(9)¡¡Pardon M, Joubert C, Perez-Diaz F, Christen Y, Launay J, Cohen-Salmon C (2000) In vivo regulation of cerebral monoamineoxidase activity in senescent controls and chronically stressedmice by long-term treatment with Ginkgo biloba extract (EGb761) Mech Ageing Dev 113:157¡Ý68
(10)¡¡Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, QuirionR (2000) The Ginkgo biloba extract (EGb 761) protectshippocampal neurons against cell death induced by betaamyloid.Eur J Neurosci 12:1882¡Ý1890
(11)¡¡Luo Y, Smith J, Paramasivam V, Burdick A, Curry K, Buford J,Khan I, Netzer W, Xu H, Butko P (2002) Inhibition of amyloidbetaaggregation and caspase-3 activation by the Ginkgo bilobaextract EGb761. Proc Natl Acad Sci USA 99:12197¡Ý12202
DeFeudis FV (1998) Ginkgo biloba extract (EGb 761): fromchemistry to clinic. Ullstein, Weisbaden, Germany
(12)¡¡Smith J, Burdick A, Golik P, Khan I, Wallace D, Luo Y (2002) Antiapoptoticproperties of Ginkgo biloba extract EGb 761 indifferentiated PC12 cells. Cell Mol Biol 48:699¡Á707
(13)¡¡Cohen-Salmon C, Venault P, Martin B, Raffalli-Sebille M, BarkatsM, Clostre F, Pardon M, Christen Y, Chapouthier G (1997)Effects of Ginkgo biloba extract (EGb 761) on learning andpossible actions on aging. J Physiol 91:291¡Ý300
(14)¡¡Smith P, Maclennan K, Darlington C (1996) The neuroprotectiveproperties of the Ginkgo biloba leaf: a review of the possiblerelationship to platelet-activating factor (PAF) J Ethnopharmacol50:131¡Ý139
(15)¡¡DeFeudis FV (2002b) Effects of Ginkgo biloba extract (EGb 761)on gene expression: possible relevance to neurologicaldisorders and age-associated cognitive impairment. Drug DevRes 57:214¡Ý235
(16)¡¡Oberpichler H, Sauer D, Rossberg C, Mennel HD, Krieglstein J(1990) PAF antagonist ginkgolide B reduces postischemicneuronal damage in rat brain hippocampus. J Cereb Blood FlowMetab 10:133¡Ý135
Æî¥ß¥·¥·¥Ã¥ÔÂç³Ø¤Î J. V. Smith »á¡¢ Y. Luo »á¤Ë¤è¤ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¥ì¥Ó¥å¡¼¤ò¤´¾Ò²ð¤·¤Þ¤·¤ç¤¦¡£
¡Ö¥®¥ó¥³ ¥Ó¥í¥Ð ¥¨¥¯¥¹¥È¥é¥¯¥È ( ¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹ ) ¤Îʬ»Ò³ØŪ¥á¥«¥Ë¥º¥à¤Ë´Ø¤¹¤ë¸¦µæ¡×
Studies on molecular mechanisms of Ginkgo biloba extract Appl Microbiol Biotechnol (2004) 64: 465¡Ý472 J. V. Smith . Y. Luo
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ë¤Ï£²¤Ä¤ÎÀ®Ê¬¤¬¤¢¤ê¡¢¤½¤ì¤é¤¬¥æ¥Ë¡¼¥¯¤ÊÌôÍýºîÍѤò¤â¤Ã¤Æ¤¤¤ë¤È¤¤¤¦¤È¤³¤í¤«¤é¤³¤Î¥ì¥Ó¥å¡¼¤Ï»Ï¤Þ¤ë¡£
1)¥Æ¥ó¥Ú¥ë
2)¥Õ¥é¥Ü¥Î¥¤¥É
1)¥Æ¥ë¥Ú¥ó¤Ï¼¡¤ËʬÎव¤ì¤ë¡£
a)¥®¥ó¥³¥é¥¤¥É A¡¢B¡¢C¡¢J¡¢M
b)¥Ó¥í¥Ð¥é¥¤¥É
a)¥®¥ó¥³¥é¥¤¥É¤Î¸ú²Ì
¡Ö ¥®¥ó¥³¥é¥¤¥É¤Ï·ì¾®ÈijèÀ²½°ø»Ò (PAF) ¤Î¥¢¥ó¥¿¥´¥Ë¥¹¥È¤Ç¡¢·ì¾®ÈijèÀ²½¤ª¤è¤Ó¶Å½¸¤òÁ˳²¤¹¤ë¡£¤½¤ì¤Ë¤è¤Ã¤Æ·ì±Õ½Û´Ä¤ò²þÁ±¤¹¤ë ¡×¡Ê1¡Ë
¥¢¥ó¥¿¥´¥Ë¥¹¥È¤È¤Ï¤¢¤ëºîÍѤòÁ˳²¤¹¤ëʪ¼Á (Ùɹ³Êª¼Á) ¡£
¤Ä¤Þ¤ê¥®¥ó¥³¥é¥¤¥É¤Ï·ìÀò¤Î·ÁÀ®¤òËɤ°¤³¤È¤¬´üÂԤǤ¤ë¡£
2)¥Õ¥é¥Ü¥Î¥¤¥É¤Î¸ú²Ì
¥Õ¥é¥Ü¥Î¥¤¥É¤Ï¹³»À²½ºîÍѤòȯ´ø¤¹¤ë¡£
¡Ö ¥Õ¥é¥Ü¥Î¥¤¥É¤Ï˧¹á´Ä¤ª¤è¤ÓÆó½Å·ë¹ç¤Ë¤è¤Ã¤Æ¹½À®¤µ¤ì¤Æ¤¤¤ë¡£¤½¤ì¤Ë¤è¤Ã¤Æ¡¢¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤Ë¤è¤êÈ¿±þ¤·¤ä¤¹¤¯¡¢Ä¾ÀÜŪ¥¹¥«¥Ù¥ó¥¸ºîÍѤòͤ¹¤ë ¡×(2)
¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤Ï¥Õ¥ê¡¼¥é¥¸¥«¥ë¡£
¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤Ï¾¤Îʪ¼Á¤ÈÈ¿±þ¤·¤ä¤¹¤¯¡¢Åü¡¢»é¼Á¡¢¥¿¥ó¥Ñ¥¯¡¢£Ä£Î£Á¤ò½ý¤Ä¤±¤ë¡£
¥Ë¥å¡¼¥í¥ó¤ò·ÁÀ®¤¹¤ëʪ¼Á¤Ç¤¢¤ëÉÔË°Ï»éËûÀ¤ËÂФ·¤Æ¤â¡¢¤³¤Î¥é¥¸¥«¥ë¤¬»À²½¥À¥á¡¼¥¸¤òÍ¿¤¨¤ë¡£
¥Õ¥é¥Ü¥Î¥¤¥É¤Ï¤Ä¤Þ¤ê¥Ë¥å¡¼¥í¥ó¤ò»À²½¤«¤é¼é¤ë¤³¤È¤¬´üÂԤǤ¤ë¡£
¤µ¤é¤Ë
¡Ö SOD ( superoxide dismutase ) ¤Î¤è¤¦¤Ê¹³»À²½¥¿¥ó¥Ñ¥¯¼Á¤Îȯ¸½¡¢¥°¥ë¥¿¥Á¥ª¥ó¤Î¤è¤¦¤Ê¹³»À²½Âå¼Õʪ¼Á¤òÁý²Ã¤µ¤»¤ë ¡×(3)¡¨(4)
SOD¤È¤ÏÁ°½Ð¤Î¥Ò¥É¥í¥¥·¥ë¥é¥¸¥«¥ë¤ò̵³²²½¤¹¤ë¹ÚÁǤΤ³¤È¡£
¤È¤³¤í¤¬SOD¤Ï²ÃÎð¤Ëȼ¤¤¸º¾¯¤·¤Æ¤·¤Þ¤¦¡£
¤·¤«¤·¥Õ¥é¥Ü¥Î¥¤¥É¤ÏSOD¤òÁý²Ã¤µ¤»¤ë¡£
¡Ö ¥Õ¥é¥Ü¥Î¥¤¥É¾å¤Î¿å»À´ð¤Ï prooxidant transitional metal ions (Î㤨¤ÐFe2+) ¤È·ë¹ç¤·¤Æ¥¥ì¡¼¥È´Ä¤òºî¤ë ¡×(3)
¡Ö ¤½¤ì¤Ë¤è¤ê¿·¤¿¤Ê¥Ò¥É¥í¥¥·¥é¥¸¥«¥ë¤ÎÀ¸À®¤òÁ˳²¤¹¤ë ¡×(2)¡¨(5)
Å´¤Ï»¬¤Ó¤ä¤¹¤¤¡£
¤½¤ì¤ÏÀ¸ÂÎÆâ¤ÎÅ´¤Ç¤âƱ¤¸¤Ç¤¹¡£
¾åµ¤Ï¡¢¥Õ¥é¥Ü¥Î¥¤¥É¤¬Å´¤ÈÈ¿±þ¤·¤Æ»À²½¤òËɤ°¤È¤¤¤¦Êó¹ð¡£
¤½¤ì¤Ç¤Ï¤½¤ì¤éÀ®Ê¬¤ò´Þ¤à¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¼çÍפʸú²Ì¤Ë¤Ä¤¤¤Æ¡£
£± ¥Õ¥ê¡¼¥é¥¸¥«¥ë¡¢»À²½¥¹¥È¥ì¥¹¤Ë¤Ä¤¤¤Æ
¡Ö ¥Õ¥ê¡¼¥é¥¸¥«¥ë¥¹¥«¥Ù¥ó¥¸¥ã¡¼³èÀ²½ºîÍѤò¤â¤Ã¤Æ¤¤¤ë ¡×
¡Ö ROS ( reactive oxygen species ) ¤ÎÁÈ¿¥ÆâÇ»ÅÙ¤ò¸º¾¯¤µ¤»¤ë ¡×(6)¡¨(7)¡¨(8)
ROS ( ³èÀ»ÀÁǼï ) ¤È¤Ï¥Õ¥ê¡¼¥é¥¸¥«¥ë¡¢³èÀ»ÀÁǤÎÁí¾Î¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¤½¤ì¤ò¸º¤é¤¹¤È¤¤¤¦¡¢¤³¤ì¤Ï¹³»À²½ºîÍѤˤĤ¤¤Æ¤ÎÊó¹ð¡£
¡Ö Ëì»é¼Á²á»À²½È¿±þ¤òÍÞÀ©¤¹¤ë ¡×(6)
Ëì»é¼Á²á»À²½È¿±þ¤È¤Ï¡¢»é¼Á¤Î»À²½¤¬Ï¢º¿¤¹¤ë¤È¤¤¤¦¸½¾Ý¤Î¤³¤È¡£
¤¢¤ë¤¤Ã¤«¤±¤Ç¿åÁǤò°ú¤È´¤«¤ì¤¿»é¼Á¤Ï¡¢¥Õ¥ê¡¼¥é¥¸¥«¥ë¤È²½¤¹¡£
¤½¤ì¤¬¤³¤ÎÏ¢º¿¤Î»Ï¤Þ¤ê¡£
¥é¥¸¥«¥ë²½¤·¤¿»é¼Á¤Ï¾¤Îʪ¼Á¤«¤éÅŻҤòÃ¥¤¤¥é¥¸¥«¥ë¤òÁý¤ä¤·¤Æ¤æ¤¯¡£
Áý¤¨¤¿¥é¥¸¥«¥ë¤Ï·òÁ´¤Ê»é¼Á¤Î¿åÁǤò¤Ä¤®¤Ä¤®°ú¤¤Ì¤¯¡£
¤È¤¤¤¦¤è¤¦¤Ë¡¢Ëì»é¼Á²á»À²½È¿±þ¤È¤Ï¡¢¤¤¤ï¤Ð»é¼Á¥¾¥ó¥Ó²½¸½¾Ý¡£
¤½¤·¤Æ¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¤½¤ÎÏ¢º¿È¿±þ¤òÍÞÀ©¤¹¤ëƯ¤¤òͤ¹¤ë¡£
¤Á¤Ê¤ß¤Ë¡¢
¥Ó¥¿¥ß¥óE¤â»é¼Á¥é¥¸¥«¥ë¤ò¸µ¤ËÌ᤹ʪ¼Á¡£
¤¿¤À¤·¡¢¥Ó¥¿¥ß¥ó£Å¤Î¥µ¥×¥ê¥á¥ó¥ÈÀݼè¤Ï¿Î̤ˤʤê¤ä¤¹¤¯ÃæÀ»éËäò°ú¤¾å¤²¤«¤Í¤Ê¤¤¤Î¤ÇÃí°Õ¤¬É¬Íס£
»é¼Á¤Î»À²½¤òËɤ°¤¿¤á¤Î¥µ¥×¥ê¥á¥ó¥È¤òÁª¤Ö¤Ê¤é¡¢¥Õ¥é¥Ü¥Î¥¤¥É¤¬Îɤ¤¤Ç¤·¤ç¤¦¡£
2 ¹³¥¹¥È¥ì¥¹ºîÍÑ
¡Ö Éû¿ÕÈé¼Á¤ÎPBR ( peripheral-type benzodiazepine receptor ) ¤Îȯ¸½¤ò¸º¤é¤¹ ¡×(6)
PBR¤È¤Ï¡¢Ëö¾¿·¿¥Ù¥ó¥¾¥¸¥¢¥¼¥Ô¥ó¼õÍÆÂΤΤ³¤È¤Ç¥³¥ë¥Á¥¾¡¼¥ë¤Î¹çÀ®¤Ë¤«¤«¤ï¤ë¼õÍÆÂΤΤ³¤È¡£
Éû¿ÕÈé¼Á¤Ë¿¤¯Â¸ºß¤·¤Æ¤¤¤ë¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¥³¥ë¥Á¥¾¡¼¥ë¤ÎÀ¸»ºÎ̤ò¸º¤é¤¹¤è¤¦¤Ç¤¢¤ë¡£
¥³¥ë¥Á¥¾¡¼¥ë¤ÏÀ¸Â¸¤ËÉԲķç¤Ê¥Û¥ë¥â¥ó¤Ç¤Ï¤¢¤ë¤â¤Î¤Î¡¢À¸ÂΤËÍÍ¡¹¤Ê¾ã³²¤ò°ú¤µ¯¤³¤¹¥Û¥ë¥â¥ó¤Ç¤â¤¢¤ë¡£
¤¿¤È¤¨¤Ð¥³¥ë¥Á¥¾¡¼¥ë¤ÎÂçÎÌȯÀ¸¡¢¤¹¤Ê¤ï¤Á¥¹¥È¥ì¥¹¤Ï¡¢³¤ÇϤò°Ñ½Ì¤µ¤»¤«¤Í¤Þ¤»¤ó¡£³¤ÇϤΥ˥塼¥í¥ó¤¬»àÌǤ·¤Æ¤¤¤Þ¤¹¡£
³¤ÇϤˤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤ¬Â¿¤¯¤¢¤ê¤Þ¤¹¡£
¡ÊÊ¢Éô¤â¿¤¯¤Æ¡¢¤À¤«¤é¥¹¥È¥ì¥¹¤Ï¤Ò¤È¤òÂÀ¤é¤»¤ë¡£¤¬¡¢¤½¤ì¤Ï¤Þ¤¿Ê̤ʵ¡²ñ¤Ë¡Ë
³¤ÇϤÏÀ¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤È¡Ö¸Æ¤Ó¤«¤±¤ë¡×´ï´±¤Ç¤¢¤ë¤¿¤á¡¢¥³¥ë¥Á¥¾¡¼¥ë¤ÎÌðÌ̤ËΩ¤Ä»ÅÁȤߤǤ¹¡£
¤·¤«¤·²á¾ê¤Ê¥³¥ë¥Á¥¾¡¼¥ë¤Ï¡ÊËýÀŪ¤Ê¥¹¥È¥ì¥¹¤Ï¡Ë³¤ÇϤΥ˥塼¥í¥ó¤ò¡Ö¶½Ê³ÆÇÀ»à¡×¤Ø¤ÈÄɤ¤¹þ¤ß¤«¤Í¤Þ¤»¤ó¡£
¡Ö¶½Ê³ÆÇÀ»à¡×¤È¤¤¤¦¸½¾Ý¤Ï¥Ë¥å¡¼¥í¥ó¤¬»àÌǤ¹¤ë»ÅÁȤߤΤҤȤĤǤ¹¡£
²á¾ê¤Ë»É·ã¤µ¤ì¤¿¥Ë¥å¡¼¥í¥óÆâ¤Ë¥«¥ë¥·¥¦¥à¥¤¥ª¥ó¤¬ÂçÎ̤ËήÆþ¤·¡¢¥Ë¥å¡¼¥í¥ó¤¬¶½Ê³¾õÂ֤Ȥʤꡢ²á³èÆ°¤òµ¯¤³¤·¡¢Èè¤ì²Ì¤Æ¡¢»àÌǤ¹¤ë¡¢¤È¤¤¤¦¸½¾Ý¡£
³¤ÇϤε¡Ç½¤Ë¤Ä¤¤¤Ï¤´¾µÃΤȻפ¤¤Þ¤¹¤¬¡¢Ç°¤Î¤¿¤á¡£
³¤ÇϤϵ²±¤òÄêÃ夵¤»¤¿¤êµ²±¤ò¸Æ¤Óµ¯¤·¤¿¤ê¤¹¤ëµ²±¤ÎÅý¹ç´ï´±¤Ç¤¢¤ê
¤Þ¤¿³¤ÇϤÏÀ¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤Èž¤¸¤ë¥¹¥¤¥Ã¥Á¤Ç¤â¤¢¤ë¡£
²Ã¤¨¤Æ³¤ÇϤÏÂç¿Í¤Ç¤¢¤Ã¤Æ¤â¥Ë¥å¡¼¥í¥ó¤¬¿·À¸¤·¡¢°é¤Ä¾ì½ê¡£
¡Ö Ǿ¤Î¥â¥Î¥¢¥ß¥ó»À²½¹ÚÁÇ ( MAO ) ³èÀ¤òÄã²¼¤µ¤»¤ë ¡×(9)
MAO ( ¥â¥Î¥¢¥ß¥ó¥ª¥¥·¥À¡¼¥¼ ) Á˳²Ìô¤ÏǾ¤Î¥É¡¼¥Ñ¥ß¥óÇ»ÅÙ¤ò¾å¤²¤ë¡£
MAOÁ˳²Ìô¤Ï¡¢¥¢¥á¥ê¥«¤Ç¤Ï¹³¤¦¤ÄºÞ¤È¤·¤Æ¤â»È¤ï¤ì¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£
¤³¤ì¤¹¤Ê¤ï¤Á¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¹³¤¦¤ÄºîÍѤò¼¨¤¹Êó¹ð¤Ç¤¹¡£
3 ¥Ë¥å¡¼¥í¥ó¤Î¥¢¥Ý¥È¡¼¥·¥¹¤Ø¤ÎºîÍÑ
¡Ö ¥Ë¥å¡¼¥í¥ó¤Î¥¢¥Ý¥È¡¼¥·¥¹¤Î¸º¾¯ ¡×(10)¡¨(11)¡¨(12¡Ë
¥¢¥Ý¥È¡¼¥·¥¹¤È¤Ï¥×¥í¥°¥é¥à¤µ¤ì¤¿ºÙ˦¤Î»àÌÇ¡¢ºÙ˦¤Î¼«»¦¤È¸À¤ï¤ì¤ë¸½¾Ý¤Ç¡¢¥Ë¥å¡¼¥í¥ó»àÌǸ¶°ø¤Î¤Ò¤È¤Ä¡£
4 ǧÃε¡Ç½¡¢µ²±¤Ø¤Î¸ú²Ì
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤ÎÉÕÃå¤ò²þÁ±¤¹¤ë¤È¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¡Ö ¿À·Ð²êºÙ˦¼ðºÙ˦¤Ë¤ª¤±¤ë¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Î¶Å½¸ÍÞÀ© ¡×(11)
¡Ö °Õ»×·èÄêǽÎϤä¹âÎðưʪ¤Ë¤ª¤±¤ë¿·¤·¤¤¥¹¥¥ë¤Î½¬ÆÀ¡¢¥¹¥È¥ì¥¹¤Ø¤Î±þÅú¤äµ¤Ê¬¤ÎÊѲ½¤È¤¤¤Ã¤¿°ø»Ò¤ËÂФ·¤ÆÍ±× ¡×(9)¡§(13)
£Ä£Î£Á¤¬Â»½ý¤ò¼õ¤±¡¢°Û¾ï¤Ê¥«¥¿¥Á¤Î¥¿¥ó¥Ñ¥¯¼Á¤òºî¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£
¤¿¤È¤¨¤ÐǾÆâ¤Ë¤ª¤¤¤Æ¤Ï¡¢¥¿¥ó¥Ñ¥¯¼Á¤ÎÀ½Â¤¤Î²áÄø¤Ç¡¢ËÜÍè¡¢Æ⦤ËÀޤꤿ¤¿¤Þ¤ì¤ë¤Ù¤ÌýÀÉôʬ¤¬³°¤Ë¤à¤½Ð¤·¤È¤Ê¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£
¤½¤ì¤é°Û¾ï¤Ê¥¿¥ó¥Ñ¥¯¼ÁƱ»Ö¤ÏÌþÃ夷¡¢²ô¤È²½¤·¤Æ¤æ¤¯¡£
¤³¤Î²ô¤Ï¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤È¸Æ¤Ð¤ì¤Þ¤¹¡£
¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Ï¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤θ¶°ø¤Î¤Ò¤È¤Ä¤È¤â¸«¤é¤ì¤Æ¤¤¤Þ¤¹¡£
¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤¬ÉÕÃ夷¤¿¥Ë¥å¡¼¥í¥ó¤Ï¤ä¤¬¤Æ¿ê¼å¤·¡¢»àÌǤ¹¤ë¤³¤È¤¬Ê¬¤«¤Ã¤Æ¤¤¤Þ¤¹¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¤½¤Î¿ê¼åÃʳ¬¤Ë¤¢¤ë¥Ë¥å¡¼¥í¥ó¤ò²óÉü¤µ¤»¤ë¤È¤ÎÊó¹ð¤â¤¢¤ê¤Þ¤¹¡£
¾åµ¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤¬¥¢¥ß¥í¥¤¥É¥Ù¡¼¥¿¤Î·ÁÀ®¤òÍÞÀ©¤¹¤ë¤È¤¤¤¦Êó¹ð¤Ç¤¹¡£
¤Á¤Ê¤ß¤Ë¤³¤Î¥ì¥Ó¥å¡¼¤Ë¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Îµ²±ÎϲþÁ±ºîÍѤòÊó¹ð¤¹¤ëÏÀʸ¤Î°úÍѤϤ¢¤ê¤Þ¤»¤ó¤¬¡¢¤½¤Î²ÄǽÀ¤ò¼¨¤¹ÏÀʸ¤ò¸«¤Ä¤±¤ë¤³¤È¤Ï¤Ç¤¤Þ¤¹¡£
ʬ»Ò¥ì¥Ù¥ë¤Ç¤Ï¡¢¤¿¤È¤¨¤Ð NDMA¼õÍÆÂΡÊĹ´üµ²±¤Ë´Ø·¸¤¹¤ë¼õÍÆÂΡˤΥΥ寥¢¥¦¥È¥Þ¥¦¥¹¤Ë¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤òÍ¿¤¨¡¢µ²±ÎϤ¬Ìá¤Ã¤¿Åù¡¢Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
5 ·ì±Õ¡¢·ìή¡¢·ì´É¤Ø¤ÎºîÍÑ
¡Ö ·ì¾®ÈijèÀ²½°ø»Ò PAF ÍÞÀ©¸ú²Ì¤Ë¤è¤ëǾµõ·ì¤Î²þÁ± ¡×(10)
¡Ö ÆâÈéͳÍè·ì´ÉÃд˰ø»Ò EDRF (Stimulation of endothelium-derivedrelaxing factor) ¤Î»É·ã¤Ë¤è¤ëÆ°Ì®¡¢ÀÅÌ®¤ª¤è¤ÓÌӺٴɤν۴IJþÁ± ¡×(14)
·ì´É¤Î¤â¤Ã¤È¤âÆ⦤˸ºß¤¹¤ëÆâÈé¤ÏÍÍ¡¹¤Êʪ¼Á¤òʬÈ礷¤Þ¤¹¡£
EDRF (NO °ì»À²½ÃâÁÇ) ¤â¤½¤Î¤¦¤Á¤Î¤Ò¤È¤Ä¡£
°ì»À²½ÃâÁǤϷì´É¤òÃдˤµ¤»¤ë¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤¬·ìή¤òÎɤ¯¤¹¤ë¤È¤¤¤¦¤Î¤Ï¤³¤Î¤¿¤á¤È¹Í¤¨¤é¤ì¤ë¡£
5 ¿À·ÐÅÁãʪ¼Á¤Ø¤ÎºîÍÑ
¡Ö ǾÆâ¤Î¦Á1-¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΡ¢5-HT1A ( ¥»¥í¥È¥Ë¥ó ) ¼õÍÆÂΤª¤è¤Ó¥à¥¹¥«¥ê¥ó¼õÍÆÂΤÎǯÎð¤Ë¤è¤ë¸º¾¯Í½ËÉ ¡×(6)
¡Ö ³¤ÇϤιâ¿ÆÏÂÀ¥³¥ê¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤Î¼è¤ê¹þ¤ß¤ÎÁý²Ã ¡×(6)
¥·¥Ê¥×¥¹Á°ºÙ˦¤«¤éÊü½Ð¤µ¤ì¤¿¥¢¥»¥Á¥ë¥³¥ê¥ó¤Ï¡¢¥·¥Ê¥×¥¹¸åºÙ˦¤Î¼õÍÆÂΤò³èÀ²½¤·¤¿¤¢¤È¤Ç¡¢µÞ®¤Ëʬ²ò¤µ¤ì¤Þ¤¹¡£ ¥³¥ê¥ó¥¨¥¹¥Æ¥é¡¼¥¼¤Ë¤è¤Ã¤Æ¥³¥ê¥ó¤È¿Ý»À¤Ë¡£
¥·¥Ê¥×¥¹¤Ï¿®¹æÅÁã¤ò¤¹¤ë¤¿¤á¤Ë¥¢¥»¥Á¥ë¥³¥ê¥ó¤òºÆÅÙ¡¢ÊÝͤ·¤Ê¤±¤ì¤Ð¤Ê¤ê¤Þ¤»¤ó¡£
¤·¤«¤·¥Ë¥å¡¼¥í¥ó¤Ï¥¢¥»¥Á¥ë¥³¥ê¥ó¤Î¸¶ÎÁ¤Ç¤¢¤ë¥³¥ê¥ó¤òºî¤ì¤Þ¤»¤ó¤Î¤Ç¡¢Ê¬²ò¤µ¤ì¤Æ¼þ°Ï¤òɺ¤¦¥³¥ê¥ó¤ò¡¢ºÆÅÙ¡¢¥·¥Ê¥×¥¹Æâ¤Ë¼è¤ê¤³¤àɬÍפ¬¤¢¤ê¤Þ¤¹¡£
³¤ÇϤιâ¿ÆÏÂÀ¥³¥ê¥ó¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤È¤Ï¡¢¤½¤ì¤é¥³¥ê¥ó¤Î¼è¤ê¹þ¤ß¸ý¤Î¤³¤È¤Ç¤¹¡£
¤Ä¤Þ¤ê¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¥¢¥»¥Á¥ë¥³¥ê¥ó¤òÁý¤ä¤¹¤è¤¦¤Ç¤¹¡£¡Ê¥³¥ê¥ó¤Î¥ê¥µ¥¤¥¯¥ë¸úΨ¤ò¸þ¾å¤µ¤»¤ë¡Ë¡Ê¤Á¤Ê¤ß¤Ë¹âÎï¿Í»²¥¨¥¥¹¤Ë¤â¤³¤ÎƯ¤¤¬¤¢¤ê¤Þ¤¹¡Ë
¥¢¥»¥Á¥ë¥³¥ê¥ó¤Ï¡¢µ²±¤Î·ÁÀ®¡¢³Ø½¬¡¢¹ÔÆ°¡¢¿ç̲¤Ë´Ø·¸¤¹¤ë¿À·ÐÅÁãʪ¼Á¤Ç¤¢¤ë¤³¤È¤Ï¤´¾µÃΤ«¤È»×¤¤¤Þ¤¹¡£
7 ¹³¥¹¥È¥ì¥¹ºîÍÑ¡¢°äÅÁ»Òȯ¸½¤Ø¤ÎºîÍѤʤÉ
¡Ö ³¤ÇϤΥ°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤΥÀ¥¦¥ó¥ì¥®¥å¥ì¡¼¥·¥ç¥ó¤ÎÁ˳² ¡×(6)
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¡¢¥¹¥È¥ì¥¹¤Ø¤ÎÄñ¹³ÎϤò¹â¤á¤ë¤È¤¤¤¦Êó¹ð¡£
³¤ÇϤΥ°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤθº¾¯¤ò¤¯¤¤¤È¤á¤ë¤È¤¤¤¦¤³¤ÎºîÍѤϡ¢¤¢¤ë¼ï¤Î¹³¤¦¤ÄÌôƱÍͤÎƯ¤¡£
¥°¥ë¥³¥³¥ë¥Á¥³¥¤¥É¼õÍÆÂΤȤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤǤ¹¡£
¤½¤Î¼õÍÆÂΤγèÀ²½¤È¤Ï¡¢À¸ÂΤΥ¹¥È¥ì¥¹È¿±þ¤òÍÞÀ©¤Ø¤ÈÀÚ¤êÂؤ¨¤ë¤¿¤á¤Ë½ÅÍס£
³¤ÇϤˤϥ³¥ë¥Á¥¾¡¼¥ë¤Î¼õÍÆÂΤ¬Â¿¤¯¤¢¤ê¡¢¤½¤ì¤æ¤¨²á¾ê¤Ê¥³¥ë¥Á¥¾¡¼¥ë¤Ï³¤ÇϤòÇ˲õ¤¹¤ë¤È¤¤¤¦¤Î¤¬Àè¤Û¤É¤Î¤ªÏä·¡£
¡Ö ¤¢¤ëÆÃÄê¤Î°äÅÁ»Ò¤Îž¼Ì¤òÄ´À᤹¤ë¡£¤½¤Î·ë²Ì¡¢ºÙ˦¤Î¹³»À²½¾õÂÖ¤òÁý²Ã¤µ¤»¡¢»À²½¥¹¥È¥ì¥¹ÂÑÀ¤ò¶¯²½¡¢ÅÁ㥢¥»¥Á¥ë¥³¥ê¥ó¤ÎÎ̤âÁý¤¨¤ë¡×(15)
¡Ö DNA¹çÀ®¤ä½¤Àµ¡¢ºÙ˦¼þ´ü¤Ë¤ª¤±¤ëµ¡Ç½¤Ë´Ø¤ï¤ë¥¿¥ó¥Ñ¥¯¼Á¤ÎÊѲ½¤Ë±Æ¶Á¤ò¤¢¤¿¤¨¡¢DNA»½ý¤òÍÞÀ©¤¹¤ë¡×(15)
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï°äÅÁ»Òȯ¸½¤ËºîÍѤ·¡¢¹³»À²½ÎϤζ¯¤¤¥Ë¥å¡¼¥í¥ó¤Ë¶¯²½¤¹¤ëƯ¤¤òͤ¹¤ë¡£
8 ¤½¤Î¾
¡Ö ¥ß¥È¥³¥ó¥É¥ê¥¢¤Î¸ÆµÛÄ´ÀáÈæΨ¤ÎÁý²Ã¤Ë¤è¤ëATP¥ì¥Ù¥ë¤òÁý²Ã ¡×(1)
¤³¤ì¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤ÏÀ¸ÂÎÆâ¤Î¥¨¥Í¥ë¥®¡¼¤òÁý¤ä¤¹¤È¤¤¤¦Êó¹ð¡£
¤Û¤«¤Ë¤â¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¹â»³É¤Ë͸ú¤Ç¤¢¤ë¤È¤¤¤¦Êó¹ð¤â¤¢¤ë¡£
¤³¤ì¤¬°ÕÌ£¤¹¤ë¤Î¤Ï»ÀÁǤμè¤ê¹þ¤ß¸úΨ¤ò¾å¤²¤ë¤È¤¤¤¦¤³¤È¤Ç¤¹¡£
Æü¾ïÀ¸³è¤Î¤Ê¤«¤Ç¤â»ÀÁǤμè¤ê¹þ¤ß¤Î¸º¤ë»öÂ֤Ϥ¿¤Ó¤¿¤ÓÀ¸¤¸¤Þ¤¹¡£
½¸Ã椹¤ë¤È¤¡¢¤ï¤¿¤·¤¿¤Á¤Ï¸ÆµÛ¤ò¤Ä¤¤Ëº¤ì¤¬¤Á¡£
½¸Ã椷¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¤È¤¤Ë¤Ï¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤òÀݤê¤Þ¤·¤ç¤¦¡£
¡Ö ¹³±ê¾ÉºîÍѤª¤è¤ÓǾ¾ã³²¤ËÂФ¹¤ëÊݸîºîÍÑ ¡×(16)
¡Ö ¿À·Ð¤Î²ÄµÕÀ¤Ø¤Î±Æ¶Á ¡×(6)¡¨(3)
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Ï¼å¤Ã¤¿¥Ë¥å¡¼¥í¥ó¤ò²óÉü¤µ¤»¤ë¤è¤¦¤Ç¤¢¤ë¡£
¤·¤«¤·¤³¤³¤Ç¤ÎÌäÂê¤Ï¡¢¥Õ¥Ä¥¦¤Î¤Ò¤È¡¢¤Ç¤Ï¤Ê¤¯¡¢Æ¬Ç¾Àï»Î¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤Î¥Ý¥Æ¥ó¥·¥ã¥ë¤ò¤É¤¦°ú¤½Ð¤¹¤«¡¢¤È¤¤¤¦¤³¤È¤Ç¤·¤ç¤¦¡£
¤ª´«¤á¤¹¤ë¤Î¤Ï¡¢¹âÎï¿Í»²¥¨¥¥¹¤ä¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÈÁȤ߹ç¤ï¤»¤ë¤³¤È¤Ç¤¹¡£
¹âÎï¿Í»²¥¨¥¥¹¤Ï¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹Æ±ÍÍ¡¢¡Ö¶½Ê³ÆÇÀ»à¡×¤òÍÞ¤¨¤ëƯ¤¡¢¥¢¥»¥Á¥ë¥³¥ê¥ó¤òÁý¤ä¤¹Æ¯¤¤â´üÂԤǤ¤Þ¤¹¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤ÈÁȤ߹ç¤ï¤»¤¿¼Â¸³¤Ç¤Ï¡¢ADHD¤ò²þÁ±¤¹¤ëÊó¹ð¤â¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
½¸ÃæÎϤò¹â¤á¤ë¤³¤È¤¬´üÂԤǤ¤ë¤Î¤Ç¤¹¡£
¤µ¤é¤Ë¡¢¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤È¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¤ÎÁȤ߹ç¤ï¤»¤Ë¤Ï¡¢½¸ÃæÎÏ¡¢µ²±ÎϤò²þÁ±¤µ¤»¤ë¤³¤È¤âÊó¹ð¤â¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
¤½¤ì¤é¥µ¥×¥ê¥á¥ó¥È¤ò¸ÄÊ̤˹ØÆþ¤·¡¢¼«Ê¬¤Ë¹ç¤¦¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¡¦¥¹¥¿¥Ã¥¯¤ò¸«¤Ä¤±¤Æ¤ß¤Æ¤Ï¤¤¤«¤¬¤Ç¤·¤ç¤¦¤«¡£
¤¢¤ë¤¤¤Ï
¥¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¤ä¡¢¥¯¡¼¥ë¥¹¥¦¥£¥Ã¥Á COOL SWITCH¤Ë¤Ï¡¢¤½¤ì¤éÊó¹ð¤È¤Û¤ÜƱÎ̤Υ¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¡¢¹âÎï¿Í»²¥¨¥¥¹ (COOL SWITCH¤Ï¥¢¥á¥ê¥«¿Í»²)¡¢¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥»¥ê¥ó¡¢¥Ð¥³¥Ñ¥â¥Ë¥¨¥é¥¨¥¥¹¤¬Ç۹礵¤ì¤Æ¤¤¤Þ¤¹¡£
¥¤¥Á¥ç¥¦ÍÕ¥¨¥¥¹¤òñÆȤÇÀݤë¾ì¹ç¤È¡¢¥¥í¥ó¤Î¥¹¥¦¥£¥Ã¥Á SWITCH ¡¢COOL SWITCH ¤È¤ò°û¤ßÈæ¤Ù¤Æ¤ß¤ë¤Æ¤âÌÌÇò¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£
¥¹¥¦¥£¥Ã¥Á¤Ï¡¢¥¢¥Þ¥¾¥ó¤ä³ÚÅ·¤Ç¤âÆþ¼ê¤Ç¤¤Þ¤¹¡£
¢§¥¢¥Þ¥¾¥ó COOL SWITCH
https://www.amazon.co.jp/dp/B07P9XSK2G/
¢§¥¢¥Þ¥¾¥ó SWITCH
https://www.amazon.co.jp/dp/B0095GON76
¢§¥¢¥Þ¥¾¥ó HYPER SWITCH
https://www.amazon.co.jp/dp/B012QKWVMQ
References
(1)¡¡Defeudis FV (2002a) Bilobalide and Neuroprotection. Pharmacol
Res 46:565¡Ý568
(2)¡¡Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M (2002)Ginkgo biloba extract: from molecular mechanisms to the
treatment of Alzheimer's disease. Cell Mol Biol 48:613¡Ý623
(3)¡¡Gohil K, Packer L (2002) Global gene expression analysis identifiescell and tissue specific actions of Ginkgo biloba extract, EGb761. Cell Mol Biol 48:625¡Ý631
(4)¡¡Oken B, Storzbach D, Kaye J (1998) The efficacy of Ginkgo bilobaon cognitive function in Alzheimer disease. Arch Neurol55:1409¡Ý1415
(5)¡¡Ni Y, Zhao B, Hou J, Xin W (1996) Preventive effect of Ginkgobiloba extract on apoptosis in rat cerebellar neuronal cellsinduced by hydroxyl radicals. Neurosci Lett 214:115¡Ý118
(6)¡¡DeFeudis F, Drieu K (2000) Ginkgo biloba extract (EGb 761) andCNS functions: basic studies and clinical applications. CurrDrug Targets 1:25¡Ý58
(7)¡¡Lien E, Ren S, Bui H, Wang R (1999) Quantitative structure-activityrelationship analysis of phenolic antioxidants. Free Radic BiolMed 26:285¡Ý294
(8)¡¡Smith J, Luo Y (2003) Elevation of oxidative free radicals inAlzheimer's disease models can be attenuated by Ginkgo bilobaextract EGb 761. J Alzheimer's Dis 5:287¡Ý300
(9)¡¡Pardon M, Joubert C, Perez-Diaz F, Christen Y, Launay J, Cohen-Salmon C (2000) In vivo regulation of cerebral monoamineoxidase activity in senescent controls and chronically stressedmice by long-term treatment with Ginkgo biloba extract (EGb761) Mech Ageing Dev 113:157¡Ý68
(10)¡¡Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, QuirionR (2000) The Ginkgo biloba extract (EGb 761) protectshippocampal neurons against cell death induced by betaamyloid.Eur J Neurosci 12:1882¡Ý1890
(11)¡¡Luo Y, Smith J, Paramasivam V, Burdick A, Curry K, Buford J,Khan I, Netzer W, Xu H, Butko P (2002) Inhibition of amyloidbetaaggregation and caspase-3 activation by the Ginkgo bilobaextract EGb761. Proc Natl Acad Sci USA 99:12197¡Ý12202
DeFeudis FV (1998) Ginkgo biloba extract (EGb 761): fromchemistry to clinic. Ullstein, Weisbaden, Germany
(12)¡¡Smith J, Burdick A, Golik P, Khan I, Wallace D, Luo Y (2002) Antiapoptoticproperties of Ginkgo biloba extract EGb 761 indifferentiated PC12 cells. Cell Mol Biol 48:699¡Á707
(13)¡¡Cohen-Salmon C, Venault P, Martin B, Raffalli-Sebille M, BarkatsM, Clostre F, Pardon M, Christen Y, Chapouthier G (1997)Effects of Ginkgo biloba extract (EGb 761) on learning andpossible actions on aging. J Physiol 91:291¡Ý300
(14)¡¡Smith P, Maclennan K, Darlington C (1996) The neuroprotectiveproperties of the Ginkgo biloba leaf: a review of the possiblerelationship to platelet-activating factor (PAF) J Ethnopharmacol50:131¡Ý139
(15)¡¡DeFeudis FV (2002b) Effects of Ginkgo biloba extract (EGb 761)on gene expression: possible relevance to neurologicaldisorders and age-associated cognitive impairment. Drug DevRes 57:214¡Ý235
(16)¡¡Oberpichler H, Sauer D, Rossberg C, Mennel HD, Krieglstein J(1990) PAF antagonist ginkgolide B reduces postischemicneuronal damage in rat brain hippocampus. J Cereb Blood FlowMetab 10:133¡Ý135